Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amoxicillin + clavulanic acid + cefepime
- Development stage
- Unknown
- Lead developer
- Sir Run-Run Shaw Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This synergistic antibiotic combination consists of the fourth-generation cephalosporin cefepime, the penicillin amoxicillin, and the beta-lactamase inhibitor clavulanic acid. Developed and studied by researchers at Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, this triple regimen is specifically designed to combat infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. In this combination, clavulanic acid acts as a potent inhibitor of KPC enzymes, which would otherwise degrade beta-lactam antibiotics. By neutralizing these enzymes, clavulanic acid restores the antibacterial activity of cefepime and amoxicillin, allowing them to effectively inhibit bacterial cell wall synthesis. This approach provides a critical therapeutic alternative for nosocomial infections and severe sepsis where traditional carbapenems are ineffective due to high-level resistance.
- Other names
- Cefepime/amoxicillin/clavulanateFEP/AMC
02
Targets
PBP1A (Penicillin-binding protein 1A)Class A BL (Class A beta-lactamase)
Beyond the preview
Go deeper on amoxicillin + clavulanic acid + cefepime.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amoxicillin + clavulanic acid + cefepime.